Loading
Histone Deacetylase Inhibitors Research / Protein Degradation and Inhibitors / Cancer, Hypoxia, and Metabolism · Journal article
Future Medicinal Chemistry · August 13, 2026
A consensus or society position rather than new primary data.
This is a medicinal chemistry review synthesizing quinoline-based anticancer agents across multiple molecular targets from 2017 to 2026, emphasizing structure-activity relationships and rational design rather than reporting primary efficacy or safety data. It provides strategic guidance for development of next-generation agents but does not present controlled trial outcomes or definitive comparative efficacy evidence.
Systematic narrative review of medicinal chemistry advances. Cancer therapy development; general medicinal chemistry and drug design audiences. Intervention: Quinoline derivatives targeting cancer-related molecular pathways.
Quinoline derivatives show promise across kinases, metabolic enzymes, epigenetic regulators, and drug transporters as cancer therapy targets Isoform selectivity, pharmacokinetic optimization, and drug resistance remain major unresolved challenges Dual-targeting and prodrug strategies are proposed as future approaches to overcome current limitations
Isoform selectivity, pharmacokinetic optimization, and drug resistance remain major unresolved challenges
This review offers medicinal chemists and researchers a comprehensive framework for rational design and optimization of quinoline-based anticancer compounds. Clinicians and translational researchers should recognize it as a synthesis of chemistry principles rather than clinical evidence to guide treatment selection.
A systematic review synthesizing medicinal chemistry advances in quinoline derivatives for cancer therapy, providing design insights and identifying challenges rather than reporting primary clinical or preclinical data.
As stated by the source record.
This review offers medicinal chemists and researchers a comprehensive framework for rational design and optimization of quinoline-based anticancer compounds. Clinicians and translational researchers should recognize it as a synthesis of chemistry principles rather than clinical evidence to guide treatment selection.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
The quinoline nucleus is a privileged scaffold valued for its structural plasticity and synthetic accessibility. This review systematically summarizes advances in quinoline derivatives for targeted cancer therapy from 2017 to 2026, organized by major molecular target families – including kinases, metabolic enzymes, epigenetic regulators, drug transporters, and others – with emphasis on rational design, key structure-activity relationships (SARs), and antitumor efficacy. Despite progress, challenges such as isoform selectivity, suboptimal pharmacokinetics, and drug resistance persist; future efforts should focus on dual-targeting and prodrug strategies to overcome these limitations. This review aims to provide medicinal chemistry insights for the design of next-generation quinoline-based anticancer agents with improved selectivity, pharmacokinetic properties, and ability to overcome drug resistance.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.